Vera Therapeutics (VERA) Non Operating Investment Income (2021 - 2024)
Vera Therapeutics' (VERA) quarterly Non Operating Investment Income came in at -$7000.0 in Q2 2024, up 75.0% YoY from -$4000.0 in Q3 2023, and down 75.0% on a QoQ basis from -$4000.0 in Q1 2024.
Powered by 
Analysis
Vera Therapeutics (VERA) Non Operating Investment Income (2021 - 2024) Analysis & Trends
Vera Therapeutics (VERA) has 4 years of Non Operating Investment Income data on file, last reported at -$7000.0 in Q2 2024.
- Quarterly Non Operating Investment Income rose 75.0% year-over-year to -$7000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$28000.0 (up 90.51% YoY) and the FY2023 annual result came in at -$47000.0, up 94.19% from the prior year.
- Non Operating Investment Income eased to -$7000.0 in Q2 2024, from -$4000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of -$1000.0 in Q1 2023 to a low of -$364000.0 in Q3 2021.
- A 4-year average of -$135230.8 and a median of -$64000.0 in 2022 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income soared 99.65% — and 2024, when it sank 300.0%.
- Tracing VERA's Non Operating Investment Income over 4 years: stood at -$247000.0 in 2021, then surged by 74.09% to -$64000.0 in 2022, then jumped by 96.88% to -$2000.0 in 2023, then tumbled by 250.0% to -$7000.0 in 2024.
- The last three Non Operating Investment Income figures came in at -$7000.0 (Q2 2024), -$4000.0 (Q1 2024), and -$2000.0 (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Vera Therapeutics | 2.56 Bn | 2.56 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -28,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | -64,000.00 |
| Sep 30, 2022 | -202,000.00 |
| Jun 30, 2022 | -256,000.00 |
| Mar 31, 2022 | -287,000.00 |
| Dec 31, 2021 | -247,000.00 |
| Sep 30, 2021 | -364,000.00 |
| Jun 30, 2021 | -281,000.00 |